Literature DB >> 2449756

Vasoactive intracavernous pharmacotherapy.

A A Sidi1.   

Abstract

The use of vasoactive intracavernous pharmacotherapy for the treatment of impotence is rapidly expanding because of its effectiveness and the rarity of short-term complications. To minimize complications, careful selection of candidates, cautious dosage determination, and thorough instruction on injection technique are mandatory. Sustained erection should be treated with alpha-adrenergic agents after 4 to 6 hours. Frequent follow-up is mandatory after home injection begins to detect the development of penile abnormalities. Longer follow-up and additional studies are required to determine the types and incidences of long-term adverse effects of the technique.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2449756

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  4 in total

Review 1.  Intracavernous prostaglandin E1 in erectile dysfunction.

Authors:  O I Linet; L L Neff
Journal:  Clin Investig       Date:  1994-01

2.  Correlation between intracavernous papaverine injection, Doppler analysis and cavernosography in impotent patients.

Authors:  Y S Sargin; H A Ozen; I Başar; A Ergen; I Celebi; D Erol; C Koçal; D Remzi
Journal:  Int Urol Nephrol       Date:  1991       Impact factor: 2.370

3.  Penile erections induced by vasoactive intestinal peptide and sodium nitroprusside.

Authors:  R Wang; T R Higuera; S C Sikka; R K Minkes; J A Bellan; P J Kadowitz; F R Domer; W J Hellstrom
Journal:  Urol Res       Date:  1993-01

4.  Our experience in the treatment of priapism.

Authors:  Dmytro Vorobets; Oleg Banyra; Alexander Stroy; Alexander Shulyak
Journal:  Cent European J Urol       Date:  2011-06-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.